The Medicines Co.

The Medicines Co.

The Medicines Co.

Date Founded



8 Sylvan Way, Parsippany, NJ, 07054, USA

Type of Company


Employees (Worldwide)



Hospitals & Patient Services
Wholesale: Consumer Non-Durables/Sundries

Company Description

The Medicines Co We are a global pharmaceutical company focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. In the United States, we have three marketed products, Angiomax® (bivalirudin) for Injection, Cleviprex® (clevidipine) Injectable Emulsion, and Argatroban Injection, 50 mg per 50 mL†. We also have a pipeline of acute and intensive care hospital products in development, including three late-stage development product candidates, cangrelor, oritavancin and MDCO-157, and two early stage development product candidates, MDCO-2010 and MDCO-216. We believe that Angiomax, Cleviprex and our products in development possess favorable attributes that can satisfy unmet medical needs in the acute | intensive care hospital product market and offer, or, in the case of our products in development, have the potential to offer, improved performance to hospital businesses. The Company is publicly traded on the Nasdaq exchange under the ticker symbol MDCO. It was founded in 1996 and employs approximately 425 professionals.

Contact Data
Trying to get in touch with decision makers at The Medicines Co.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Senior Vice President & Chief Financial Officer

Executive Vice President & General Counsel

Chief Commercial Officer

Chief Development Officer

Chief Human Strategy Officer

Executive Vice President



Engagement Partner

Paths to The Medicines Co.
Potential Connections via
Relationship Science
The Medicines Co.
Owners & Shareholders
Details Hidden

FCM seeks to achieve superior risk-adjusted rates of return through a process of fundamental analysis that emphasizes capital preservation. The firm uses the following sources: a variety of publicly available information sources, including but not limited to financial periodicals, corporate rating services, annual reports, prospectuses and filings with the SEC and other regulators, company press releases, as well as, and to the extent applicable or appropriate, information provided by management and creditors of portfolio companies, brokers, dealers, analysts, professional asset managers, research services and hired consultants and advisers. Historically, FCM's core strategies have included merger arbitrage, credit investments, real estate investments, direct investments and long/short equity. They make investments in public and private debt and equity securities, as well as direct investments in private companies and real estate.

Details Hidden

OP manages a macro strategy based on a top-down thematic investment approach. The firm seeks to identify and exploit a handful of macroeconomic themes likely to persist over the medium term. They invest across multiple asset classes, and emphasize portfolio construction, hedging techniques, disciplined trading and strict exposure guidelines.OP previously managed a global equity strategy following a bottom-up event-driven investment approach and invested in equity and equity derivatives with a focus on companies undergoing significant corporate events which the firm deemed having a predictible outcome.

Details Hidden

Magnetar Financial implements a variety of different strategies in managing private investment funds and separately managed accounts (SMAs) which designed to achieve attractive risk-adjusted rates of return. Some of the funds and SMAs employ a multi-strategy approach, utilizing a wide range of strategies across a range of geographies, while others focus on one or just a few strategies. It may hold both long and short positions in a broad range of securities, derivatives, and other assets. In executing their investment strategies, the funds and SMAs may enter into joint venture or co-investment arrangements, participate in pooled investment vehicles, invest with affiliated or unaffiliated advisors or managers, or make direct investments in operating entities. Magnetar Financial may use leverage in the investing activities and may engage in short selling. The firm's main investment strategies are divided into the following categories: relative-value, event-driven, directional, hybrid and other investment strategies.

Recent Transactions
Details Hidden

Novartis AG purchases The Medicines Co.

Details Hidden

The Medicines Co. issued USD Common Stock

Details Hidden

Melinta Therapeutics, Inc. purchases Medicines Co. /Infectious Disease Business Unit from The Medicines Co.

Transaction Advisors

Advised onThe Medicines Co. issued USD Common Stock

Legal Advisor

Advised onThe Medicines Co. purchases Targanta Therapeutics Corp.


Advised onThe Medicines Co. issued USD Common Stock

Co-Chair, Life Sciences Group

Advised onThe Medicines Co. purchases Targanta Therapeutics Corp.

Legal Advisor

Advised onThe Medicines Co. purchases Targanta Therapeutics Corp.

Legal Advisor

Advised onMelinta Therapeutics, Inc. purchases Medicines Co. /Infectious Disease Business Unit from The Medicines Co.

Advisors & Consultants
Legal Advisor

Shareholder at Greenberg Traurig LLP

Legal Advisor

Partner at Wilmer Cutler Pickering Hale and Dorr LLP


Chief Executive Officer & President at IVERIC bio, Inc.


Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

SciClone Pharmaceuticals is a US-based, China-focused specialty pharmaceutical company with a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders. SciClone’s ZADAXIN® (thymalfasin) is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV) and certain cancers, and as a vaccine adjuvant, according to the local regulatory approvals. Besides ZADAXIN, SciClone markets about 14 mostly partnered products in China, including Depakine®, the most widely prescribed broad-spectrum anti-convulsant in China; Tritace®, an ACE inhibitor for the treatment of hypertension; Stilnox®, a fast-acting hypnotic for the short-term treatment of insomnia (marketed as Ambien® in the US); and Aggrastat®, a recently-launched interventional cardiology product. SciClone is also pursuing the registration of several other therapeutic products in China. SciClone is headquartered in Foster City, California.

Key Stats and Financials As of
Market Capitalization
Total Enterprise Value
Earnings Per Share
Non-Profit Donations & Grants
$10K - $15K
$5,000 - $10K
Political Donations
Details Hidden

Annovation BioPharma, Inc. develops pharmaceutical products in the field of anesthesia, sedation and sleep. It is developing a rapid-acting anesthesia called Rapidate. The firm's novel agents are designed to allow more precise control of anesthesia and enable safer treatment of patients undergoing surgical procedures. The company was founded in 2009 by Nicholas Barker and is headquartered in Parsippany, NJ.

Details Hidden

Managing Partner at Amzak Capital Management LLC

Details Hidden

Former Chief Executive Officer at Curacyte AG

Details Hidden

Co-Founder at The Medicines Co.

Hospira, Inc. Pharmaceuticals | Lake Forest, IL

Hospira, Inc. provides injectable drugs and infusion technologies. It offers drugs, IV sets and clinical integration, infusion pumps, clinical software and implementation services. The company was founded on September 16, 2003 and is headquartered in Lake Forest, IL.

Alnylam Pharmaceuticals, Inc. Medical Support Services | Cambridge, Massachusetts

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Agilent Technologies, Inc. Computer Software | Santa Clara, CA

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that enable to identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment comprises activity providing active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software, and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Esperion Therapeutics, Inc. Pharmaceuticals - Ann Arbor, Michigan

Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Sanofi Pharmaceuticals - Paris, France

Sanofi, a diversified global healthcare leader, discovers, develops, and distributes therapeutic solutions to improve the lives of everyone. We work to prevent and treat the diseases that we know of today, as well as those we may face tomorrow. With nearly 100,000 dedicated professionals in more than 100 countries, Sanofi is devoted to advancing healthcare around the world. Sanofi US, with headquarters in Bridgewater, New Jersey, along with our vaccines division, Sanofi Pasteur, employs more than 11,400 professionals throughout the country. At Sanofi, we work for what really matters: health

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by The Medicines Co.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of The Medicines Co.'s profile does not indicate a business or promotional relationship of any kind between RelSci and The Medicines Co..